Top

The European Journal of Health Economics

Published in:

01-10-2012 | Original Paper

Disease progression and costs of care in Alzheimer’s disease patients treated with donepezil: a longitudinal naturalistic cohort

Authors: Anders Gustavsson, Linus Jönsson, Johan Parmler, Niels Andreasen, Carina Wattmo, Åsa K. Wallin, Lennart Minthon

Published in: The European Journal of Health Economics | Issue 5/2012

Abstract

Background/Aims

Improved data and methods are needed for modeling disease progression in Alzheimer’s disease (AD) for economic evaluation of treatments. The aim is to estimate prediction models for long-term AD progression and subsequently economic outcomes.

Methods

Three-year follow-up data on 435 patients treated with the cholinesterase inhibitor donepezil in clinical practise were analyzed. Regression models were estimated for long-term prediction of decline in cognitive function (ADAS-cog) and activities in daily living (ADL) ability, risk of institutionalization and costs of care.

Results

The cognitive deterioration was estimated at between 1.6 and 4 ADAS-cog points per every 6 months, increasing with disease severity. Cognitive function was an important predictor of ADL-ability, which itself was the most important predictor of the risk of institutionalization and costs of care. Combining all models in a cross-validation process generated accurate predictions of costs of care at each 6 months follow-up.

Conclusion

The proposed methods for representing AD progression and economic outcomes can be used in micro-simulation models for the economic evaluation of new treatments.

Henderson, A.S., Jorm, A.F.: Definition and epidemiology of dementia: a review. In: Maj, M., Sartorius, N. (eds.) Dementia. Wiley, Chichester (2000)

Jönsson, L., Berr, C.: Cost of dementia in Europe. Eur. J. Neurol. 12(1), 50–53 (2005)PubMedCrossRef

Lemstra, A.W., Richard, E., van Gool, W.A.: : Cholinesterase inhibitors in dementia: yes, no, or maybe? Age Ageing 36, 625–627 (2007)PubMedCrossRef

Clegg, A., Bryant, J., Nicholson, T., McIntyre, L., De Broe, S., Gerard, K., Waugh, N.: Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer’s disease. A systematic review. Int. J. Technol. Assess. Health Care 18, 497–507 (2002)PubMedCrossRef

Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P., Whalen, E.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 57, 613–620 (2001)PubMedCrossRef

Wimo, A., Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wetterholm, A.L., Mastey, V., Haglund, A., Zhang, R., Miceli, R., Chin, W., Subbiah, P.: An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trial. Dement. Geriatr. Cogn. Disord. 15, 44–54 (2003)PubMedCrossRef

Wimo, A., Winblad, B., Stoffler, A., Wirth, Y., Mobius, H.J.: Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics 21, 327–340 (2003)PubMedCrossRef

Black, S.E., Doody, R., Li, H., McRae, T., Jambor, K.M., Xu, Y., Sun, Y., Perdomo, C.A., Richardson, S.: Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 69, 459–469 (2007)PubMedCrossRef

Jonsson, L.: Assessing health economic outcome in Alzheimer’s disease clinical trials. J. Nutr. Health Aging 11, 353–355 (2007)PubMed

10.

Jonsson, L., Jonsson, B., Wimo, A., Whitehouse, P., Winblad, B.: Second International Pharmacoeconomic Conference on Alzheimer’ s Disease. Alzheimer Dis. Assoc. Disord. 14, 137–140 (2000)PubMedCrossRef

11.

Cohen, J.T., Neumann, P.J.: Decision analytic models for Alzheimer’s disease: state of the art and future directions. Alzheimers Dement 4, 212–222 (2008)PubMedCrossRef

12.

Jones, R.W., McCrone, P., Guilhaume, C.: Cost effectiveness of memantine in Alzheimer’s disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 21, 607–620 (2004)PubMedCrossRef

13.

Fagnani, F., Lafuma, A., Pechevis, M., Rigaud, A.S., Traykov, L., Seux, M.L., Forette, F.: Donepezil for the treatment of mild to moderate Alzheimer’s disease in France: the economic implications. Dement. Geriatr. Cogn. Disord. 17, 5–13 (2004)PubMedCrossRef

14.

Zhu, C.W., Scarmeas, N., Torgan, R., Albert, M., Brandt, J., Blacker, D., Sano, M., Stern, Y.: Clinical characteristics and longitudinal changes of informal cost of Alzheimer’s disease in the community. J. Am. Geriatr. Soc. 54, 1596–1602 (2006)PubMedCrossRef

15.

Zhu, C.W., Scarmeas, N., Torgan, R., Albert, M., Brandt, J., Blacker, D., Sano, M., Stern, Y.: Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease. Neurology 67, 998–1005 (2006)PubMedCrossRef

16.

Murman, D.L., Von Eye, A., Sherwood, P.R., Liang, J., Colenda, C.C.: Evaluated need, costs of care, and payer perspective in degenerative dementia patients cared for in the United States. Alzheimer Dis. Assoc. Disord. 21, 39–48 (2007)PubMedCrossRef

17.

Loveman, E., Green, C., Kirby, J., Takeda, A., Picot, J., Payne, E., Clegg, A.: The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol. Assess. 10:iii–iv, ix–xi, 1–160 (2006)

18.

Frances, A.: American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV: Prepared by the Task Force on DSM-IV, 4th edn. American Psychiatric Association, Washington, DC (1994)

19.

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M.: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34, 939–944 (1984)PubMedCrossRef

20.

Wallin, A.K., Andreasen, N., Eriksson, S., Batsman, S., Nasman, B., Ekdahl, A., Kilander, L., Grut, M., Ryden, M., Wallin, A., Jonsson, M., Olofsson, H., Londos, E., Wattmo, C., Eriksdotter Jonhagen, M., Minthon, L.: Donepezil in Alzheimer’s disease: what to expect after 3 years of treatment in a routine clinical setting. Dement. Geriatr. Cogn. Disord. 23, 150–160 (2007)PubMedCrossRef

21.

Rosen, W.G., Mohs, R.C., Davis, K.L.: A new rating scale for Alzheimer’s disease. Am. J. Psychiatry 141, 1356–1364 (1984)PubMed

22.

Lawton, M.P., Brody, E.M.: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9, 179–186 (1969)PubMedCrossRef

23.

Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wimo, A., Wetterholm, A.L., Zhang, R., Haglund, A., Subbiah, P.: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57, 489–495 (2001)PubMedCrossRef

24.

Winblad, B., Wimo, A., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wetterholm, A.L., Haglund, A., Zhang, R., Schindler, R.: 3-year study of donepezil therapy in Alzheimer’s disease: effects of early and continuous therapy. Dement. Geriatr. Cogn. Disord. 21, 353–363 (2006)PubMedCrossRef

25.

Jönsson, L., Eriksdotter Jonhagen, M., Kilander, L., Soininen, H., Hallikainen, M., Waldemar, G., Nygaard, H., Andreasen, N., Winblad, B., Wimo, A.: Determinants of costs of care for patients with Alzheimer’s disease. Int. J. Geriatr. Psychiatry 21, 449–459 (2006)PubMedCrossRef

26.

Socialstyrelsen.: Kostnad per brukare i kommunal vård och omsorg. http://www.skl.se/MediaBinaryLoader.axd?MediaArchive_FileID=7cd49b6c-30eb-4a00-8635-c9919a5656a5 (2005). Accessed 5 July 2011

27.

Dunn, G., Mirandola, M., Amaddeo, F., Tansella, M.: Describing, explaining or predicting mental health care costs: a guide to regression models. Methodological review. Br. J. Psychiatry 183, 398–404 (2003)PubMedCrossRef

28.

Faber, N.M., Rajko, R.: How to avoid over-fitting in multivariate calibration–the conventional validation approach and an alternative. Anal. Chim. Acta 595, 98–106 (2007)PubMedCrossRef

29.

Wattmo, C., Hansson, O., Wallin, A.K., Londos, E., Minthon, L.: Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting. Dement. Geriatr. Cogn. Disord. 26, 203–211 (2008)PubMedCrossRef

30.

Stern, R.G., Mohs, R.C., Davidson, M., Schmeidler, J., Silverman, J., Kramer-Ginsberg, E., Searcey, T., Bierer, L., Davis, K.L.: A longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration. Am. J. Psychiatry 151, 390–396 (1994)PubMed

31.

Galasko, D.R., Gould, R.L., Abramson, I.S., Salmon, D.P.: Measuring cognitive change in a cohort of patients with Alzheimer’s disease. Stat. Med. 19, 1421–1432 (2000)PubMedCrossRef

32.

Liu, X., Teresi, J.A., Waternaux, C.: Modelling the decline pattern in functional measures from a prevalent cohort study. Stat. Med. 19, 1593–1606 (2000)PubMedCrossRef

33.

Murman, D.L., Chen, Q., Powell, M.C., Kuo, S.B., Bradley, C.J., Colenda, C.C.: The incremental direct costs associated with behavioral symptoms in AD. Neurology 59, 1721–1729 (2002)PubMedCrossRef

34.

Mesterton, J., Wimo, A., By, A., Langworth, S., Winblad, B., Jonsson, L.: Cross sectional observational study on the societal costs of Alzheimer’s disease. Curr. Alzheimer Res. 7, 358–367 (2010)PubMedCrossRef

35.

Gustavsson, A., Brinck, P., Bergvall, N., Kolasa, K., Wimo, A., Winblad, B., Jonsson, L.: Predictors of costs of care in Alzheimer’s disease: a multinational sample of 1222 patients. Alzheimers Dement 7, 318–327 (2011)PubMedCrossRef

Title: Disease progression and costs of care in Alzheimer’s disease patients treated with donepezil: a longitudinal naturalistic cohort
Authors: Anders Gustavsson
Linus Jönsson
Johan Parmler
Niels Andreasen
Carina Wattmo
Åsa K. Wallin
Lennart Minthon
Publication date: 01-10-2012
Publisher: Springer-Verlag
Published in: The European Journal of Health Economics / Issue 5/2012
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-011-0334-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Disease progression and costs of care in Alzheimer’s disease patients treated with donepezil: a longitudinal naturalistic cohort

Abstract

Background/Aims

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background/Aims

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2012

Health economics and health technology assessment in Central and Eastern Europe: a dose of reality

The sustainability of European health care systems: beyond income and aging

Loss of labour productivity caused by disease and health problems: what is the magnitude of its effect on Spain’s Economy?

Genetic testing in the European Union: does economic evaluation matter?

The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country

Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale